NEXLIZET is a combination of 2 medicines, bempedoic acid and ezetimibe. The bempedoic acid portion of NEXLIZET was studied in a large clinical trial on reducing heart attack and heart …

Sep 26, 2024 · Nexlizet may cause the following serious side effects. Increased levels of uric acid in your blood (hyperuricemia). This can happen within 4 weeks of starting Nexlizet and can …

Adverse reactions led to discontinuation of treatment in 8% of patients on NEXLIZET, 5% of patients on placebo, 10% of patients on bempedoic acid, and 12% of patients on ezetimibe.

The most common adverse reactions in the cardiovascular outcomes trial for bempedoic acid, a component of NEXLIZET and NEXLETOL, at an incidence of ≥2% and 0.5% greater than …

May 27, 2025 · Nexlizet (bempedoic acid/ezetimibe) is a prescription tablet used to help lower cholesterol and reduce the risk of heart attack as well as heart surgery. Nexlizet is prescribed …

Apr 10, 2024 · Nexlizet (bempedoic acid and ezetimibe) contains an adenosine triphosphate -citrate lyase (ACL) inhibitor and a cholesterol absorption inhibitor and is used as an adjunct to …

Nexlizet is indicated as an adjunct therapy to diet and maximally-tolerated statin therapy. Nexlizet is a combination treatment of two drugs, bempedoic acid and ezetimibe. Bempedoic acid is a …

Apr 4, 2025 · Dosage for reducing certain cardiovascular risks Nexlizet is approved to help reduce the risk of heart attack and coronary revascularization (a type of heart procedure) in certain …

Bempedoic acid, a component of NEXLIZET, is used: to lower the risk of major adverse cardiovascular (CV) events, such as death from cardiovascular disease, heart attack, stroke, …

The most common side effects of NEXLIZET in people with heart problems include: Kidney problems, anemia, increased liver enzymes, muscle spasms, and gallstones NEXLIZET can …